Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ark Genomic Revolution ETF (NY: ARKG )

26.56 +0.54 (+2.08%)
Streaming Delayed Price Updated: 11:53 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ark Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 Next >
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage. 
Via Talk Markets
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE: 
Via Benzinga
Mike Khouw Sees Unusual Options Activity In ARK Genomic Revolution ETF
On CNBC's "Options Action," Mike Khouw said ARK Genomic Revolution ETF (BATS: ARKG) was active on Tuesday as it traded six times its average daily put volume.... 
Via Benzinga
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
ETF Battles ARKG Vs. GNOM - What's The Better Genomic/Biotech Play?
Each ETF is judged against the other in key categories like cost, exposure strategy, performance, and a mystery category. 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
3 Healthcare Stocks Cathie Wood Loves Right Now
Here's why the founder and CEO of ARK Invest set her sights on these three healthcare stocks. 
Via The Motley Fool
Healthcare Stocks Hit New Highs but Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
Cathie Wood's Ark Adds Another $29M To Palantir Stake After Q2 Earnings Beat, Buys DraftKings On Dip
Cathie Wood-led Ark Invest on Friday snapped up 1.156 million shares — estimated to be worth about $28.78 million — in... 
Via Benzinga
Topics Earnings
Exposures Financial
Palantir, Alibaba, Square, Twitter, DraftKings — Stocks Cathie Wood's Ark Bought Or Sold On Thursday
Cathie Wood-led Ark Invest on Thursday increased the exposure in Palantir Technologies Inc (NYSE... 
Via Benzinga
Teladoc's Earnings Had 1 Important Metric for Both Bulls and Bears
Which story do you believe? 
Via The Motley Fool
As Zymergen Crashes 76%, Cathie Wood Piles Up $2.5M Worth Of Shares
A bullish Ark Invest on Wednesday more than doubled its stake in Zymergen Inc (NASDAQ: ZY) after it plummeted due to the company’s “immaterial” revenue... 
Via Benzinga
Q2 Growth 'Nothing Short Of Virtuous': Economist
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic. What... 
Via Benzinga
Exposures COVID-19
Cathie Wood Doubles Down On Teladoc, Spotify, Shopify As Stocks See Earnings-Related Dips
Cathie Wood-led Ark Investment Management on Wednesday piled up 713,842 shares, estimated to be worth about $108.37 million, in 
Via Benzinga
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood's genomics ETF is making big bets on the "Genomic Age." 
Via The Motley Fool
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
Cathie Wood Piles On Another $59M In Uipath, Sells $2.6M In Roku
Cathie Wood-led Ark Investment Management on Tuesday snapped up 858,129 shares, estimated to be worth about $59.12 million, in UiPath Inc (NYSE: PATH) on the dip. Shares of the... 
Via Benzinga
These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval
Some might be surprised to see income-paying stocks among the ARK Invest founder's high-growth picks. 
Via The Motley Fool
Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M
Cathie Wood-led Ark Investment Management on Friday snapped up 136,859 shares, estimated to be worth about $9.55 million, in UiPath Inc 
Via Benzinga
Cathie Wood Loads Up On Quantum-Si For 6th Straight Session: What You Should Know About This Chip Stock
Cathie Wood-led Ark Investment Management has quickly piled up over one million shares in the semiconductor company Quantum-Si Inc... 
Via Benzinga
Top-Performing Biotech ETFs of Last Week
Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week. 
Via Talk Markets
Biotech Movers During ASCO Week
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval. 
Via Talk Markets
Has Illumina Lost Its Shine?
Cathie Wood lost her conviction and dumped the stock. Can Illumina get back on track? 
Via The Motley Fool
Topics Regulatory Compliance
Exposures Legal Regulatory
Cathie Wood, Bullish On Bitcoin, Lifts Coinbase Stake Above $1B, Snaps Up More UiPath Shares
Cathie Wood-led Ark Investment Management on Thursday snapped up more shares in Coinbase Global Inc (NASDAQ: 
Via Benzinga
2 Biotech Stocks ARK Invest Bought in June
Should you follow Cathie Wood's latest genomic revolution investments? 
Via The Motley Fool
Can Cathie Wood's Favorite Healthcare Company Make You Rich?
Multiple purchases in Wood's ETFs appear to be a strong endorsement of the company. 
Via The Motley Fool
The Best Stocks to Buy in Cathie Wood's ARK Genomic Revolution ETF
Two big biotech stocks and one smaller life sciences stock especially stand out. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.